Dr. Zelefsky, a director of the company, is a nationally and internationally recognized Radiation Oncologist who is Associate Professor of Radiation Oncology at Memorial Sloan-Kettering Cancer Center in New York where he is also the Chief of the Brachytherapy Service. His primary clinical focus is in the treatment of Genitourinary Cancers including prostate and bladder cancers as well as Head and Neck Cancers. He has been the Principal Investigator on many clinical research studies, which have included protocols incorporating novel drugs in conjunction with radiotherapy for the treatment of locally advanced cancers. Dr Zelefsky has been the Principal Investigator who tested Imclone’s C225 in conjunction with chemo-radiotherapy for advanced Head and Neck Cancer as well as the current PI on a Phase III randomized trial supported in part by Astra Zeneca testing the role of hormone therapy in conjunction with high-dose radiotherapy. He has published well over 150 peer-reviewed articles, chapters and review articles. He is the Editor in Chief of Brachytherapy, the premier journal in the country on Brachytherapy in the management of cancer and is the Chairman of the National Patterns of Care Study- Genitourinary Section. He has been selected as one of the Best Doctors in New York and also chosen as one of top Doctors in the United States in the Castle Connolly listing for 2003.
